

## Enabling Breakthrough Immunotherapies via Novel Routes of Drug Delivery



NASDAQ: TLSA

## **Disclaimer and Forward-Looking Statement**

The content of this presentation has been prepared for the purpose of providing general information about, and an overview of, the Company and its business. It is not intended to be a complete review of all matters concerning the Company and nor has it been independently verified. Whilst the presentation has been prepared in good faith and the Company has taken all reasonable care to ensure the information and facts contained in this presentation are accurate and up-to-date, it does not make any representation or warranty, express or implied, as to the accuracy or completeness of any information included in this presentation. Neither the Company nor any of its directors, officers, employees or agents shall be liable for any loss arising directly or indirectly from the use of or reliance upon this presentation or in relation to the adequacy, accuracy, completeness or reasonableness of the information it contains. All and any such liability is expressly excluded to the fullest extent permitted by law. The information in this presentation is subject to updating, completion, revision, further verification and amendment without notice.

This presentation does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for any securities including ordinary shares in the Company nor does it constitute an invitation or inducement to engage in investment activity in relation to any securities, including the ordinary shares of the Company. It does not purport to contain information that shall form the basis of or be relied upon in making such investment decisions. If you require any advice, please consult with a professional financial adviser. All investments are subject to risk. The value of securities may go down as well as up. Past performance cannot be relied on as a guide for future performance.

This presentation may contain certain forward-looking statements concerning the financial condition, results of operations and businesses of the Company. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in these statements. All forward-looking statements contained in this presentation are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. You should not place undue reliance on forward-looking statements. Each forward-looking statement speaks only as of the date of this presentation. The Company does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information. In light of these risks, results could differ materially from those stated, implied or inferred from the forward-looking statements contained in this presentation.

In the UK, this presentation has not been approved by an authorised person and is being distributed on the basis that each person in the UK to whom it is issued is reasonably believed to be such a person as is described in Article 19 (investment professionals) or Article 49 (high net worth companies, unincorporated associations etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) or are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated. Persons who do not fall within such descriptions may not act upon the information contained in this presentation.



## **Investment Highlights**





Innovative, clinicallyvalidated, drug delivery platform enabling improved delivery routes for immunotherapies. Recent clinical data support the MOA Global IP protection of antibody formulation technology until 2040, can be applied across different molecules. Strong IP protection for lead assets Milciclib and Foralumab

Partnership with Precision Biosciences for lymphodepletion ahead of CAR-T procedures. Collaboration ongoing Targeting the global \$150+ billion market for antibody treatments<sup>1</sup>. Clinical data validate MOA for nasal administration




Experienced scientific advisory board and management team that has brought four drugs to market. Demonstrated Bench to market experience



# The Antibody Market is Enormous and Offers Significant Opportunities for Reformulation

Global Market was Valued at \$150 Billion in 2019 and is Expected to Grow to \$300 Billion by 2025<sup>1</sup>




Source: <sup>1</sup> Lu et al. Journal of Biomedical Science (2020) 27:1



## **A Revolutionary Platform**

Antibody Administration: Switching From IV and SC To Oral, Nasal And Inhaled Routes



## Benefits of non-systemic dosing

- Improved patient compliance
- Local activity instead of systemic distribution; may minimize side effects
- Anticipated lower cost of goods and lower price of administration



## **Our Pipeline**

Five Clinical Studies completed. All with positive data

	Subject	PC	IND	Phase 1/IAP	Phase 2	Phase 3
<b>FORALUMAB</b> Fully human anti-CD3 mAb	Intranasal	Progressive Multiple Sclerosis (expanded program)			Ongoing IAP, 6 months data showed positive clinical response	
	Oral	Crohn's Disease			2Q 2022 Phase 1b	
	Subcutaneous	Type 1 Diabetes			2Q-2022 IND Submission	
ANTI IL-6 RECEPTOR Fully human mAb	Inhalation	Pulmonary Fibrosis			3Q-2022 IND Submission	
<b>MILCICLIB</b> Pan-CDK inhibitor	Oral	Milciclib + Gemcitabine	in NSCLC Kras+ mutants		2Q-2022 IND Submission	



## **Near-Term Milestones**

#### 1Q 2022

#### FORALUMAB

#### T1 Diabetes (Sub-cutaneous)

Submission of IND and initiation of Phase 1a trial in healthy volunteers

#### Crohn's disease (oral)

Amended Protocol for evaluation of potential 'take-home' oral capsules in mild to moderate Crohn's Disease patients has been submitted.

#### Multiple sclerosis (intranasal)

Readout of 6-month clinical data in secondary progressive multiple sclerosis (SPMS) in the first patient under the individual patient access (IPA) program.

2Q 2022

#### FORALUMAB

#### Multiple sclerosis (intranasal)

Readout of 6-month clinical data in secondary progressive multiple sclerosis (SPMS) reported: Positive clinical responses. Second patient 3-months data anticipated May 2022.

#### Crohn's disease (oral)

Initiation of trial with 'take-home' oral capsules in mild to moderate Crohn's Disease patients. May 2022

#### **MILCICLIB**

#### **KRAS+ NSCLC (oral)**

Filing of IND and Initiation of Phase 2 trial in KRAS+ NSCLC patients with combination of milciclib + gemcitabine



## TLSA is Attractively Positioned Amongst Companies Developing Similar Pipeline Assets

CaplQ ID or Ticker	Company	Ticker	Market	Cap (M, USD)	Therapeutic Focus
TLSA	Tiziana Life Sciences PLC	TLSA	\$	78.9	Immunology, Oncology and Virology
DTIL	Precision BioSciences, Inc.	DTIL	\$	260.08	Oncology (CAR-T)
NKTX	Nkarta, Inc.	NKTX	\$	308.74	Oncology (CAR-NK)
PRVB	Provention Bio, Inc.	PRVB	\$	413.20	Immunology (Type 1 Diabetes)
TGTX	TG Therapeutics, Inc.	TGTX	\$	1,296.41	Immunology
IMVT	Immunovant, Inc.	IMVT	\$	662.29	Immunology
ABSCF	AB Sciences S.A	ABSCF	\$	508.40	Neurodegenerative
MNOV	MediciNova, Inc	MNOV	\$	118.19	Neurodegenerative
ALT	Altimmune, Inc.	ALT	\$	359.97	Intranasal Vaccine



# Lead Asset:

## Foralumab

The only **fully human** anti-CD3 monoclonal antibody in clinical studies


Non-FC binding anti-CD3 antibody mutations expected to have improved safety profile

\*\*

\*\*


## Foralumab is the Only Fully Human Anti-CD3 mAb in Clinical Trials

**CD3-specific Monoclonal Antibodies in Clinical Development** 



Adapted from: Kuhn, Chantal, and Howard L. Weiner. "Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside." Immunotherapy 8.8 (2016): 889-906.







#### Precision Biosciences (Nasdaq: DTIL) Licensing Collaboration Validates Our Technology

First foralumab Program to be Tested Will be in Combination with an Anti-CD19 CAR-T

- Exclusive agreement allowing Precision to explore Tiziana's fully human anti-CD3 monoclonal antibody (mAb), foralumab, as an agent to induce tolerance of allogeneic CAR-T cells to potentially improve the clinical outcome of Precision's CAR-T cell therapy programs
- Foralumab to be used as a potential mild preconditioning and lymphodepleting agent to replace or reduce doses of cyclophosphamide/fludarabine (Cy/Flu)

#### Upfront payments



- Multiple payments commensurate with meeting specified successful milestones
- Royalties
- Additional royalty options for subsequently developed CAR-T products
- Precision to be responsible for the development, commercialization and costs for use of foralumab




Intranasal Foralumab for Treatment of Neurodegenerative Diseases (Multiple Sclerosis)

Local activity with improved safety and lowered dosing


### Fully Human Anti-CD3 mAb

## Intranasal




## Intranasally-Administered Foralumab for Neurodegenerative Diseases

An Innovative Approach to Penetrate the Blood Brain Barrier (BBB)






## Intranasally-Administered Foralumab Mechanism of Action (Validated in Animal Studies)



## Effective in suppressing symptoms of multiple sclerosis (MS) in animal studies



100 -50 -50 -1C aCD3 Cognitive Behavior

 $\star \star \star$ 

<sup>1</sup> Rotarod = forced motor activity performance test


<sup>2</sup>EAE = experimental autoimmune encephalitis



Work completed by Prof. Howard Weiner. Mayo, Lior, et al. "IL-10-dependent Tr1 cells attenuate astrocyte activation and ameliorate chronic central nervous system inflammation." Brain 139.7 (2016): 1939-1957.

## Foralumab: Clinical Proof of Concept for Intranasal Delivery First Demonstrated in Mild-to-Moderate COVID-19


The First Validation That Intranasally Administered Foralumab is Well-tolerated and the Treatment Provides Clinical Benefits



#### **Results: Biomarkers measured via cytokines and C-reactive proteins**

Cohort	Lung CT Scan	Cytokine IL-6	<b>C-Reactive Protein</b>
Evaluable patients	% Improvement	% Reduction	% Reduction
Control, n=14	43	37	40
Foralumab + Dexa, n=12	75	41	55
Foralumab, n=10	80	69	85

#### **CT Scan of Patients' Lungs**






## Phase 1 Clinical Trial in Healthy Volunteers with Intranasally-Administered Foralumab Showed No Apparent Symptoms of Adverse Events

#### Immuno-biomarkers

**Downregulation:** Cytotoxic CD8 cells , IFN-gamma

Upregulation: IL-10, T regulatory cells (Tregs)

Tregs are capable of crossing blood-brain barrier to elicit site targeted immunomodulation



- > No Systemic Absorption (targeted effect)
- Positive outcome from Immunobiomarker analysis

Well-tolerated & no local irritation



## Intranasally Administered Foralumab in SPMS Patient: 6-Month Treatment Data

First patient was dosed with intranasal foralumab M-W-F for two weeks with a subsequent 1-week washout period for 6-month period. Data consistent with 3-month period.

**Positive Results:** The regimen was well-tolerated with associated beneficial clinical and biomarker changes.

#### **Clinical Results**

#### PET imaging data

- Indicated continued inhibition of microglial cell activation
- The reduction in microglial activation was seen in all parts of brain
- Suppression of microglial activation further increased after six months of treatment

#### **Clinical Test Evaluation**

- Improvement in Timed 25-Foot Walk Test (T25FW)
- 9-Hole Peg Test (9HPT)
- Symbol Digit Modality Test (SDMT)

#### **Biologic Response**

#### **Biomarker changes**


Downregulated serum levels of proinflammatory cytokines\*, including:

- Interferon-gamma (IFN-g)
- Interleukin (IL)-18
- IL-1b
- IL-6

\*These biomarkers are known to be associated with multiple sclerosis pathogenesis and progression



## Graph Depicting Microglial Activation PET signal in Different Regions of the Brain at Various Time Points





### Intranasally Administered Foralumab in SPMS Patient: 6-Month Treatment Data

Percent Reduction\* in Microglial PET Signal After Starting Intranasal Foralumab as Compared to Baseline, in Whole Brain and Selected Brain Regions

	WHOLE BRAIN	CEREBRAL CORTEX	THALAMUS	WHITE MATTER	CEREBELLUM
3 months	-23%	-23%	-20%	-25%	-22%
6 months	-38%	-38%	-50%	-36%	-38%

\*Percent reduction is based on changes from baseline in SUVR-1, a surrogate index for PET binding potential. SUVR=Standardized Uptake Value Ratio, calculated with reference to a pseudo reference region in cerebral white matter that showed minimal change in PET SUV, across time points.

Published PET studies have shown an increase in activated microglial cells in patients with secondary progressive MS (SPMS), and an increase associated with higher scores on the Expanded Disability Status Scale (EDSS), a widely-used scale to measure disability.




Oral Foralumab for Inflammatory Bowel Diseases (Crohn's Disease)




## Oral capsules

Foralumab, a fully human anti-CD3 mAb



## **Orally-Administered Foralumab in Phase 1a Trial in Healthy Volunteers**

Phase 1b Trial in Crohn's Disease Patients to Begin Q2 '22



### **Clinical results**

Single ascending dose, double-blind, placebo-controlled study in healthy subjects

Foralumab administered at 1.25, 2.5 and 5.0 mg/dose in entericcoated capsules

Well-tolerated at all doses tested and no drug-related safety issues observed


No systemic absorption of orally administered foralumab



# Validated Proof of Concept for Oral Administration of OKT3, an Anti-CD3 mAb, in Ulcerative Colitis

#### Key Findings

- OKT3 was approved for renal transplantation patients but is now off the market due to toxicity concerns
- Prof. Snapper, et al., of Harvard Medical School conducted an exploratory study with oral OKT3 treatmen in patients with ulcerative colitis, an inflammatory bowel
  disease



- Biologic response of increased proliferation and anti-inflammatory gene expression profile in peripheral blood mononuclear cells
- 3 of 6 patients had a clinical response including one patient in clinical remission
- Treatment was well-tolerated with no serious treatment-related adverse events
- Patients with moderate-to-severe ulcerative colitis received oral OKT3, a fully-murine anti-CD3 mAb once daily for 30 days



\* Boden, E. K., Canavan, J. B., Moran, C. J., McCann, K., Dunn, W. A., Farraye, F. A., Ananthakrishnan, A. N., Yajnik, V., Gandhi, R., Nguyen, D. D., Bhan, Aantibodies, K., Weiner, H. L., Korzenik, J. R., Snapper, S. B. Immunologic alterations associated with oral delivery of anti-CD3 (OKT3) monoclonal in patients with moderate-to-severe ulcerative colitis. Crohn's & Colitis 360 (2019). 183: 240-246.

## **Oral Milciclib for NSCLC**

Broad-spectrum inhibitory activities of milciclib on CDKs are favorable

## Milciclib CDK4 CDK7 CDK5 CDK2 CDK1 2000 Cancer cell

Specifically downregulates miR-221/miR-222 pair and c-myc.

## Phase 1 Study of Milciclib + Gemcitabine in Refractory Solid Tumors

#### **Trial Design**

16 Patients with refractory solid tumors

Treated with oral milciclib at three dose levels (45, 60, and 80 mg/m²/day)

With a fixed dose of IV gemcitabine (1000 mg/m²/day)


#### **Results**

Milciclib was well-tolerated with manageable side effects

#### **Overall response rate was 36%**

Clinical activity was observed in patients with variety of solid cancers who were non-responders to all existing chemotherapy

Recommended Phase 2 dose (RPD) found to be 80mg/m<sup>2</sup>/day



Swimmer plot showing treatment duration. Tumor type was indicated for patients having a prolonged stable disease or a partial response.

M = milciclib G = gemcitabine

Cancer Chemotherapy and Pharmacology, June 2017, 79(6), 1257-1265



## Milciclib: Successful Validation in Phase 2 trial in Sorafenib-Resistant HCC supports further testing in NSCLC with KRAS mutations

HCC is a complex and heterogenous cancer associated with multiple etiological factors that make treatment challenging and may benefit from a broadspectrum approach

Primary endpoint: Safety

✓ Well-tolerated


Treatment was well-tolerated and adverse events were manageable with no drug related deaths in the trial

#### Secondary endpoints:

- TTP 5.9 months
  - Median Time-to-Progression
- SD 61%
  - Patients with stable disease
- CBR 64%
  - Patients showed clinical benefit response

NSCLC is a complex and heterogenous cancer with multiple genetic mutations

K-RAS and EGFR mutations predominate in NSCLC





## **Executive Management Team**

Deep Drug Development Expertise with Proven Track Record; Independently Bringing Four Drugs to Market



Kunwar Shailubhai PhD, MBA CEO & CSO

Executive Director Co-founder, EVP & CSO of Synergy Pharmaceuticals, NASDAQ: SGYP Inventor of antibody oral formulation technology. Pioneer of GC-C agonist technology

Inventor of approved drug TRULANCE®. Dolcantide successfully completed Phase 2 trial

Prior experience at Callisto Pharmaceuticals (NASDAQ: CLSP) and Monsanto



Gabriele Cerrone MBA Executive Chairman

Founder and chairman of two biotech companies with market cap over \$2B

Inhibitex sale for \$2.5B

Prior experience at Synergy, Trovagene, Gensignia, Rasna, Contravir, and Siga Technologies

Co-founded NASDAQ: HEPH, CLSP, RASP, CRDF



John Brancaccio Non-Executive Director

Over 35 years financial experience in pharma/biotech/medical devices with over 15 years experience with multiple public companies

Management and SEC reporting

Private and public fundraising experience



Willy Simon Non-Executive Director

Career as an executive in the banking and corporate finance sector and director of publicly listed companies


Kredietbank N.V., Citibank, Generale Bank NL, CEO of Fortis Investment Management

Chairman of Bank Oyens & van Eeghen, Partner at Redi & Partners



## **Scientific Advisory Committee**

World renowned scientists with proven track records in drug discovery and development



#### Howard Weiner, MD

CHAIRMAN

Professor of Neurology at Harvard Medical School.

Director and Founder of the Partners MS Center and Co-Director of the Ann Romney Center for Neurologic Diseases

Pioneered investigation of the mucosal immune system for the treatment of autoimmune and other diseases



#### Kevan Herold, MD

MEMBER

Professor of Immunobiology and Medicine and Deputy Director, Yale Center for Clinical Investigation

Director of the Yale Diabetes Center and Director of the TrialNet Center at Yale

Expert in autoimmune diseases and anti-CD3 monoclonal antibody therapies



Arun Sanyal, MD

MEMBER

Charles Caravati Distinguished Professor and Chair, Division of Gastroenterology, Hepatology and Nutrition at Virginia Commonwealth University School of Medicine

Leader in the field of liver diseases



#### Napoleone Ferrara , MD MEMBER

Inventor of Avastin® (\$6.67Bn/yr)\*; 2010 Lasker Award

Senior Deputy Director Basic Sciences, Moores Cancer Center, UC San Diego

Distinguished Prof of Pathology, School of Medicine, UC San Diego



#### Tanuja Chitnis, MD

#### MEMBER

Professor of Neurology at Harvard Medical School.

Senior Scientist at the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital (BWH)

Board-certified neurologist specializing in multiple sclerosis (MS) related neuro-immunological disorders and leads several research studies and clinical trials in these areas



## **Contact Us**

#### **US Headquarters (New York)**

Tiziana Therapeutics Inc 3805 Old Easton RD Doylestown PA 18902-8400

### UK Headquarters (London)

Tiziana Life Sciences plc 55 Park Lane London W1K 1NA

+44 7769 88 4020 hmalik@tizianalifesciences.com

